A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
A phase 2 trial of Trastuzumab deruxtecan in melanoma, run by AstraZeneca, active and no longer recruiting.
Overview
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations is a phase 2 interventional study registered as NCT04639219 by AstraZeneca, with 102 participants enrolled, started 2020-12-30 and due to reach its primary completion in 2023-01-25. Interventions recorded: Trastuzumab deruxtecan. Conditions listed: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
Shares Trastuzumab deruxtecan, AstraZeneca.
- TrialTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Shares Trastuzumab deruxtecan, AstraZeneca.
- TrialA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Shares Trastuzumab deruxtecan, AstraZeneca.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Trastuzumab deruxtecan, AstraZeneca.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Trastuzumab deruxtecan, AstraZeneca.
- TrialA Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Shares Trastuzumab deruxtecan, AstraZeneca.
- TrialDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC
Shares Trastuzumab deruxtecan, AstraZeneca.
- TrialStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Shares Trastuzumab deruxtecan, AstraZeneca.